Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 5/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20363252 | 0.86 | ACACB (0.52) | ACACBPPARAPPARGELANELDHA | |
| SCHEMBL10272345 | 0.83 | ACACB (0.47) | ACACBPPARAPPARGELANELDHA | |
| SCHEMBL20363241 | 0.83 | ACACB (0.50) | ACACBPPARAPPARGELANELDHA | |
| SCHEMBL1709313 | 0.83 | PPARG (0.48) | ACACBPPARAPPARGELANELDHA | |
| SCHEMBL20363264 | 0.83 | ACACB (0.52) | ACACBPPARAPPARGELANELDHA | |
| SCHEMBL1704939 | 0.80 | ESR1 (0.46) | MAPT | |
| SCHEMBL27420078 | 0.79 | ACACB (0.49) | ACACBPPARAPPARGELANELDHA | |
| SCHEMBL20363236 | 0.79 | PPARG (0.39) | PPARAPPARGLDHAMAPT | |
| SCHEMBL1706267 | 0.78 | MAPT (0.49) | MAPT | |
| SCHEMBL1703264 | 0.78 | MAPT (0.49) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-9040531-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | ACACB 3496/4885PPARA 766/4885PPARG 773/4885 |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | ACACB 3496/4885PPARA 766/4885PPARG 773/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | ACACB 3496/4885PPARA 766/4885PPARG 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.